Cellenkos received FDA clearance for a Phase I clinical trial of its investigational new drug  CK0801 intended to treat bone marrow failure syndrome including aplastic anemia, myelodysplastic syndrome and myelofibrosis.

CK0801 is described as an ‘off-the-shelf’ cord blood derived regulatory T cell product used for treating immune dysfunction by obstructing regulators of inflammation.

The trial will begin in the third quarter of 2018 at the University of Texas’ MD Anderson Cancer Center.